Xero Revenue 31%, Shares -55%|What Is 21% Organic Growth Actually Worth?

A $2.75 Billion Company the Market Is Paying Less For Every Quarter

Xero reported operating revenue of two-point-seven-five billion Australian dollars for the year ended March 2026 — a 31 per cent jump — and the share price fell eight per cent on the day. That gap, between what the business produced and what capital is willing to price it at, is now 55 per cent wide over twelve months. The question that number forces is not whether Xero is growing. It is whether any rate of revenue growth can justify the cost structure it is building to achieve it.

The ASX 200 Index ended the session under pressure on Friday, with mining stocks dragging the benchmark lower as copper prices fell. BHP Group and Rio Tinto both gave ground. Commonwealth Bank, which lost its position as the ASX's most valuable company earlier this week, slipped further. Against that backdrop, the technology sector had been holding a relative bid — which makes Xero's inability to hold its own result all the more telling.

The accounting software company reported net profit after tax of 167 million Australian dollars, down 27 per cent from the prior year. Revenue grew at 31 per cent. Profit contracted by more than a quarter. Those two lines, moving in opposite directions at that magnitude in the same financial year, are what reset the market's valuation framework for the stock — not the revenue figure itself. At the time of reporting, Xero shares had already fallen 32 per cent in calendar 2026 before today's result was released.

The tension that session did not resolve is whether the profit decline is a one-year investment cost or the beginning of a structural compression. That distinction is what every buyer and seller of ASX: XRO is now pricing against each other.

The Melio Acquisition and What a 27% Profit Drop Signals About US Expansion

The mechanism behind the profit contraction is the Melio acquisition and Xero's accelerating push into the United States market. Organic revenue growth, stripping out Melio, came in at 21 per cent — strong by any conventional software standard, but materially below the headline 31 per cent. That difference matters because the capital cost of bridging those ten percentage points is what ate the profit.

Xero's customer base reached four-point-nine-two million, up 11 per cent on FY25. In absolute terms, that is a business adding subscribers at scale. But the cost of acquiring and integrating those customers through the US channel, combined with the Melio platform investment, reversed the profit trajectory at the exact moment the company needed institutional capital to re-rate the stock higher after a brutal twelve months.

The pattern has a precedent on the ASX. When Afterpay scaled aggressively into North America between 2019 and 2021, Australian institutional holders accepted margin compression as the price of addressable market expansion — right up until they did not. The re-rating, when it came, was not gradual. It was a single change in the discount rate applied to future free cash flow, and it came faster than the revenue line warranted. Xero's twelve-month chart, down 55 per cent against revenue growing at 31 per cent, follows that same sequence — capital withdrawing before the fundamentals have turned.

What that precedent cannot tell you is the threshold at which the US expansion starts returning capital rather than consuming it. Xero has not guided to a specific margin recovery timeline. That absence of a commitment date is precisely what the sell-off is pricing in — not the 27 per cent profit drop, but the open-ended duration of the investment cycle.

The Verification Benchmark: When Organic Growth Needs to Close the Gap

The unresolved question from Friday's result is whether 21 per cent organic growth, sustained for two or three reporting periods without further margin deterioration, is sufficient to stabilise the share price — or whether Xero needs to demonstrate Melio-related synergies in actual margin recovery before institutional positioning shifts back.

The continuation case rests on a specific condition: if Xero's FY27 result shows organic growth holding above 20 per cent while NPAT stabilises or expands even modestly, the current price — already down 55 per cent from its twelve-month peak — begins to reflect a bottom. The comparable case here is not Afterpay, which was acquired before it proved the US economics. It is REA Group, which absorbed significant offshore investment costs in the early 2020s before Australian institutional holders returned in size once the domestic margin base proved durable.

The breakdown case is equally specific. If the next result shows organic growth slipping below 18 per cent — the level at which US subscriber acquisition costs no longer scale with revenue — the argument that Melio is an investment rather than a dilution becomes structurally harder to sustain. At that point, the 55 per cent decline would not represent a buying opportunity; it would represent a correct re-rating still in progress.

The benchmark to watch before the next result is Xero's US subscriber count in the interim trading update, expected in the September quarter. A second consecutive quarter of sub-10 per cent US customer growth would signal that the acquisition premium is not converting into the market penetration the margin compression was supposed to fund. That number, more than any single analyst price target, is what determines whether the gap between 31 per cent revenue growth and a 55 per cent share price decline is eventually closed — or widened.